Sunday 18 October 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.
3.36
0.23
−6.41%
Follow UNCY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (101.07%) | (163.14%) | (141.14%) | (84.15%) |
+8 more TTM periods Free account |
|
| (69.05%) | (86.51%) | (65.73%) | (61.64%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.89%) | (107.65%) | (88.25%) | (73.83%) | |
Free Cash Flow per Share |
(1.03) | (1.20) | (1.97) | (1.65) | |
Free Cash Flow |
(27.85) | (28.67) | (31.34) | (29.88) | |
Capital Expenditures |
(0.01) | (0.02) | (0.02) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(24.28%) | (31.07%) | (43.85%) | (37.27%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (535.09) | (415.73) | (500.87) | |
Operating CF/Net income |
0.79 | 0.72 | 1.18 | 1.09 | |
Depreciation/Fixed assets |
15.61 | 13.75 | 8.67 | 7.40 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.04) | (0.08) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.03) | (1.20) | (1.97) | (1.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates